SGLT2i Prescribing Patterns Among Medically And Socially Complex Patients With Heart Failure Within An Urban Internal Medicine Teaching Clinic

Carol Fernandez Hazim,Mustafa Al-Taei,Saurabhi Samant,Katherine Di Palo

DOI: https://doi.org/10.1016/j.cardfail.2023.10.371

IF: 6.592

2024-01-01

Journal of Cardiac Failure

Abstract:Introduction The benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2i) have been shown in multiple large randomized clinical trials across the spectrum of heart failure (HF) regardless of the ejection fraction (EF) and diabetic status. Despite these data, there is still an observable discrepancy in the prescription rates in the inpatient and outpatient settings. In this study, we examined the SGLT2i prescription rates within a single internal medicine resident-run teaching clinic that serves a diverse and vulnerable patient population in the Bronx, NY, USA. Methods Using an electronic health record registry, we identified patients with a history of HF who were seen by a primary care provider at the Wakefield Ambulatory Care Center from December 2022 to March 2023. We excluded patients with an estimated GFR <30 ml/min, type 1 diabetes mellitus, and documented allergic reactions to SGLT2i. SGLT2i prescription rates were assessed based on various subcategories, including race, ethnicity, language, presence of diabetes, ejection fraction, presence of chronic kidney disease (CKD), and insurance. Chi-Square test was utilized for the comparison of independent variables. Results One hundred seventy-three patients met the inclusion criteria. The median (IQR) age was 67 (53-80) years, and 46% were females. Most patients were Non-Hispanic Black (50%), followed by Hispanic (37%), Non-Hispanic White (11%), and 15% had a preferred language of Spanish. Comorbid diabetes was observed in 53% of patients; 38% had CKD Stage 3, and 37% had an EF ≤50%. Patients with commercial insurance were more frequently prescribed an SGLT2i (41%) compared to Medicaid (28%) and Medicare (17%, p=0.05). The SGLT2i prescription rate was higher in patients with diabetes (32%) compared to those without diabetes (17%, p=0.04) and trended higher in patients with an EF ≤50% (32%) compared to EF ≥50% (20%, p=0.08). No difference in prescription rates was observed by sex, race, ethnicity, language, or CKD stage. Conclusions In a medically underserved and complex population, SGLT2i are underutilized in the primary care setting. Our study demonstrated higher prescription rates in patients with comorbid diabetes and commercial insurance. Further investigations are needed to evaluate primary care providers' barriers to SGLT2i prescription to overcome clinical inertia in patients with HF.

cardiac & cardiovascular systems